title: Posterior segment toxicity after gemcitabine and docetaxel chemotherapy.
abstract: OBJECTIVE
  To report outer retinal disruption and uveal effusion after gemcitabine and docetaxel combination therapy.
  
  
  METHODS
  A 78-year-old woman presented with blurry vision after two cycles of gemcitabine and docetaxel combination chemotherapy for stage IV sarcoma. At presentation, visual acuity was finger counting and 20/25 in the right and left eyes, respectively. Slit-lamp examination and B-scan ultrasonography revealed severe uveal effusion in the right eye and choroidal folds in the left eye. Spectral domain optical coherence tomography showed disruption of photoreceptor inner segment ellipsoid band in the right eye. The patient was monitored weekly with ophthalmic examination and B-scan ultrasonography, while continuing with gemcitabine monotherapy. At 8 weeks follow-up, uveal effusion improved considerably and visual acuity was 20/40 and 20/20 in the right and left eyes, respectively.
  
  
  CONCLUSIONS
  Uveal effusion and outer retinal disruption were reported after gemcitabine and docetaxel chemotherapy. Early detection and close ophthalmic monitoring may allow concurrent cancer treatment and prevention of possible chemotherapy-induced ocular side effects.
authors.affiliation: *MD, MPH †MD ‡PhD Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois (all authors).
authors.forename: Ali
authors.initials: A
authors.lastname: Kord Valeshabad
authors.forename: William F
authors.initials: WF
authors.lastname: Mieler
authors.forename: Vikram
authors.initials: V
authors.lastname: Setlur
authors.forename: Merina
authors.initials: M
authors.lastname: Thomas
authors.forename: Mahnaz
authors.initials: M
authors.lastname: Shahidi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D006801:Humans; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000188:drug therapy / Q000473:pathology; D020419:Photoreceptor Cells, Vertebrate / Q000187:drug effects / Q000473:pathology; D012509:Sarcoma / Q000188:drug therapy / Q000473:pathology; D043823:Taxoids / Q000009:adverse effects; D041623:Tomography, Optical Coherence / Q000379:methods; D014603:Uveal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D014786:Vision Disorders / Q000139:chemically induced / Q000175:diagnosis; D014792:Visual Acuity / Q000187:drug effects; D000093542:Gemcitabine
chemical_list: D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D000093542:Gemcitabine
references.citation: J Clin Oncol. 2000 Mar;18(6):1212-9
references.pmid: 10715290
references.citation: Cancer. 1970 Mar;25(3):571-9
references.pmid: 5416827
references.citation: Am J Ophthalmol. 1981 Apr;91(4):500-4
references.pmid: 6939330
references.citation: Invest Ophthalmol Vis Sci. 1985 Apr;26(4):580-3
references.pmid: 3980172
references.citation: Arch Ophthalmol. 1992 Aug;110(8):1150-4
references.pmid: 1386726
references.citation: Surv Ophthalmol. 2006 Jan-Feb;51(1):19-40
references.pmid: 16414359
references.citation: Am J Ophthalmol. 1999 Feb;127(2):230-3
references.pmid: 10030580
references.citation: J Clin Oncol. 1997 Sep;15(9):3149-55
references.pmid: 9294478
references.citation: Arch Ophthalmol. 2012 Jan;130(1):120-2
references.pmid: 22232485
references.citation: Retina. 2014 Jul;34(7):1261-80
references.pmid: 24949716
references.citation: Am J Clin Oncol. 2000 Apr;23(2):132-9
references.pmid: 10776972
references.citation: J Clin Oncol. 2000 Jul;18(14):2780-7
references.pmid: 10894879
references.citation: Eye Contact Lens. 2003 Apr;29(2):134-5
references.pmid: 12695719
references.citation: Br J Ophthalmol. 2003 May;87(5):648-9
references.pmid: 12714417
references.citation: Cancer. 2003 Aug 1;98(3):504-7
references.pmid: 12879466
references.citation: Cancer. 1977 Jan;39(1):58-61
references.pmid: 264409